A study from Merck Laboratories has shown cyclooxygenase-2 (COX-2) inhibitor etoricoxib (Arcoxia) to be as effective as ibuprofen for treating pain associated with arthritis. The 12-week study included 528 patients being treated for arthritis of the hip and knee and compared Arcoxia with ibuprofen and placebo.
It took about 2 weeks for Arcoxia and ibuprofen to achieve maximum effectiveness, with symptom control lasting for another 10 weeks. Both drugs performed better than placebo and generally were well tolerated. Arcoxia is a new COX-2 inhibitor and, as such, has been scrutinized by the FDA along with Vioxx and other members of that class of drugs for a possible link to heart attack and stroke.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs